Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426875 | 0.95 | AGXT (0.32) | IDO1AGXTDUTBACE1 | |
| SCHEMBL12783776 | 0.83 | IDO1 (0.35) | IDO1AGXTPREPDUTBACE1 | |
| SCHEMBL12002628 | 0.83 | IDO1 (0.46) | IDO1AGXTPREPDUT | |
| SCHEMBL4729100 | 0.81 | RAB9A (0.43) | — | |
| SCHEMBL6615170 | 0.81 | BACE1 (0.36) | IDO1AGXTBACE1 | |
| SCHEMBL3012099 | 0.80 | CYP3A4 (0.50) | IDO1 | |
| SCHEMBL15489965 | 0.78 | TDP1 (0.37) | AGXTDUTBACE1 | |
| SCHEMBL12855670 | 0.78 | AGXT (0.52) | IDO1AGXT | |
| SCHEMBL906834 | 0.78 | IDO1 (0.48) | IDO1BACE1 | |
| SCHEMBL7216290 | 0.78 | WNT3A (0.36) | IDO1AGXTPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227721-B1 | NOVEL SUBSTITUTED SUCCINIC ACID METALLO-BETA-LACTAMASE INHIBITORS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | MERCK & CO INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20030207859-A1 | Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections | BALKOVEC JAMES M (US) | 2003-11-06 | — | — | US | disclosed |
| US-6630510-B1 | Together with a beta-lactam antibiotic | MERCK & CO., INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030078418-A1 | Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections | BALKOVEC JAMES M (US) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078418-A1 | Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections | SI, ME1, ALPI | IDO1 1443/4885AGXT 178/4885PREP 53/4885 |
| US-20030207859-A1 | Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections | SI, ME1, ALPI | IDO1 1443/4885AGXT 178/4885PREP 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.